Compare Incyte Corporation (INCY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tesla, Inc. — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Tesla, Inc. trades at $378.88 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 60.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | TSLA | |
|---|---|---|
Market Cap | $23.11B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $489.88 |
52-Week Low | $67.38 | $302.63 |
Enterprise Value | $19.13B | $1.36T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $378.88, down 0.51% on the day, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with revenue declining to $94.83B in 2025 and net income margin compressing to 3.95%, while valuation multiples remain elevated with a P/E of 339.06. Recent news highlights Tesla's strategic pivot toward robotics, AI, and energy growth amid a slowing auto business, with regulatory approval for driver-assistance software in Europe providing a potential catalyst.
Tesla's investment case balances high-growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 suggests modest upside, but investors face headwinds from competitive pressures and margin compression. The stock's trajectory will likely hinge on successful commercialization of new technologies and improved automotive profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
